Early Phase 1 Pancreatic Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 or older, of any gender, who are willing and able to follow the study procedures as judged by the research team
- People who have been diagnosed with a cancerous tumour of the pancreas through pathology testing, and who had surgery to remove the tumour between 1 and 3 months ago
- People whose genetic testing showed no specific abnormalities (called copy number variations or loss of heterozygosity) in genes related to the immune system's ability to recognise cancer cells (confirm with trial site)
- People whose tumour tissue was analysed using advanced genetic testing, and where that analysis found at least one target (called a neoantigen) that the immune system may be able to recognise, including targets linked to KRAS or TP53 gene mutations
- People whose overall physical condition means the treating doctor has determined they are not well enough to tolerate chemotherapy, as measured by a standard health scoring system (ECOG score of 2 or higher)
Who may not be able to join:
- People who have received chemotherapy, certain traditional Chinese medicine treatments with anti-tumour purposes, or other anti-tumour treatments within the 4 weeks before the study drug would first be given
- People with a history of a lung condition called interstitial lung disease or pulmonary fibrosis (scarring of the lung)
- People with other serious or uncontrolled health conditions that may affect participation, including a history of severe drug allergies, known allergies to tumour vaccines or related treatment components, severe reactions to similar medications in the past, or a history of immune system deficiency conditions including HIV
- People whom the research team considers unsuitable for the trial for other reasons
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Baiyong Shen, M.D&Ph.D, Ruijin Hospital
Phone: 18817821319
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Drug related toxicity
Can't join this trial?
Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.